South Korea · Delayed Price · Currency is KRW Theragen Etex Statistics
Total Valuation
Theragen Etex has a market cap or net worth of KRW 77.95 billion. The enterprise value is 99.10 billion.
| Market Cap | 77.95B |
| Enterprise Value | 99.10B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Theragen Etex has 36.68 million shares outstanding. The number of shares has increased by 9.00% in one year.
| Current Share Class | 36.68M |
| Shares Outstanding | 36.68M |
| Shares Change (YoY) | +9.00% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 27.45% |
| Owned by Institutions (%) | 0.91% |
| Float | 24.11M |
Valuation Ratios
The trailing PE ratio is 62.58.
| PE Ratio | 62.58 |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | 7.49 |
| P/OCF Ratio | 5.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.61, with an EV/FCF ratio of 9.52.
| EV / Earnings | 79.23 |
| EV / Sales | 0.36 |
| EV / EBITDA | 5.61 |
| EV / EBIT | 8.97 |
| EV / FCF | 9.52 |
Financial Position
The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.61 |
| Quick Ratio | 1.20 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | 4.04 |
| Interest Coverage | 4.97 |
Financial Efficiency
Return on equity (ROE) is 1.98% and return on invested capital (ROIC) is 3.92%.
| Return on Equity (ROE) | 1.98% |
| Return on Assets (ROA) | 2.82% |
| Return on Invested Capital (ROIC) | 3.92% |
| Return on Capital Employed (ROCE) | 7.15% |
| Weighted Average Cost of Capital (WACC) | 4.32% |
| Revenue Per Employee | 1.23B |
| Profits Per Employee | 5.58M |
| Employee Count | 224 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 4.01 |
Taxes
In the past 12 months, Theragen Etex has paid 2.36 billion in taxes.
| Income Tax | 2.36B |
| Effective Tax Rate | 45.56% |
Stock Price Statistics
The stock price has decreased by -27.35% in the last 52 weeks. The beta is 0.16, so Theragen Etex's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -27.35% |
| 50-Day Moving Average | 2,079.20 |
| 200-Day Moving Average | 2,607.67 |
| Relative Strength Index (RSI) | 50.60 |
| Average Volume (20 Days) | 101,535 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theragen Etex had revenue of KRW 275.36 billion and earned 1.25 billion in profits. Earnings per share was 33.96.
| Revenue | 275.36B |
| Gross Profit | 143.40B |
| Operating Income | 10.78B |
| Pretax Income | 5.19B |
| Net Income | 1.25B |
| EBITDA | 17.39B |
| EBIT | 10.78B |
| Earnings Per Share (EPS) | 33.96 |
Balance Sheet
The company has 41.35 billion in cash and 42.05 billion in debt, with a net cash position of -693.38 million or -18.90 per share.
| Cash & Cash Equivalents | 41.35B |
| Total Debt | 42.05B |
| Net Cash | -693.38M |
| Net Cash Per Share | -18.90 |
| Equity (Book Value) | 143.98B |
| Book Value Per Share | 3,367.45 |
| Working Capital | 55.22B |
Cash Flow
In the last 12 months, operating cash flow was 13.94 billion and capital expenditures -3.53 billion, giving a free cash flow of 10.41 billion.
| Operating Cash Flow | 13.94B |
| Capital Expenditures | -3.53B |
| Depreciation & Amortization | 6.61B |
| Net Borrowing | -2.96B |
| Free Cash Flow | 10.41B |
| FCF Per Share | 283.68 |
Margins
Gross margin is 52.08%, with operating and profit margins of 3.91% and 0.45%.
| Gross Margin | 52.08% |
| Operating Margin | 3.91% |
| Pretax Margin | 1.88% |
| Profit Margin | 0.45% |
| EBITDA Margin | 6.31% |
| EBIT Margin | 3.91% |
| FCF Margin | 3.78% |
Dividends & Yields
Theragen Etex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.64% |
| Buyback Yield | -9.00% |
| Shareholder Yield | -9.00% |
| Earnings Yield | 1.60% |
| FCF Yield | 13.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Theragen Etex has an Altman Z-Score of 2.13 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 8 |